

PATIENT INFORMATION**Referral Status:** New Referral Updated Order Order RenewalPatient Full Name: _____ DOB: _____ Phone: _____ Gender: M F Other

Email Address: _____ Address: _____ Weight (lbs/kg): _____ Height (in): _____

 NKDA Allergies: _____ Existing prior authorization? Yes, (Send a copy) No (AIC will process)**Patient Status:** New to Therapy Continuing Therapy Last Treatment Date: _____ Next Due Date: _____**Patient Preferred Location:** _____**DIAGNOSIS & CLINICAL INFORMATION****ICD 10-Code & Description**

G30.0 Alzheimer's disease with early onset
 G30.1 Alzheimer's disease with late onset
 G30.8 Other Alzheimer's disease, unspecified
 G31.84 Mild Cognitive impairment of uncertain or unknown etiology
 Other: _____

If using CMS-approved clinical trial or registry PLEASE SELECT alongside primary diagnosis code:

Z00.6 (encounter for examination for normal comparison and control in clinical research study)

REQUIRED DOCUMENTATION: Please include insurance card (front & back), all patient demographics, history & physicals, medication lists, recent lab results (CBC, CMP, TB, Hep B panel-depending on medication) , signed prescription order and recent visit notes.

Confirm that these and the required lab orders have been sent to American Infusion Care and necessary parties.

PRESCRIPTION INFORMATION

Nursing: Provide nursing care per American Infusion Care - Specialty Infusions protocols, including reaction management and post-procedure observation

Pre-Medications

Acetaminophen (Tylenol) 500mg 650mg 1000mgPO
 Cetirizine (Zyrtec) 10mgPO
 Loratadine (Claritin) 10mgPO
 Diphenhydramine (Benadryl) 25mg 50mg PO IV
 Methylprednisolone (Solu-Medrol) 40mg 125mg IV
 Other: _____ Dose: _____ Route: _____

**MRIs should be performed at baseline & prior to the 2nd, 3rd, 4th and 7th infusion

Lab Orders

Required: TB test results, MRI within 1 year
 Cognitive Assessment Score _____
 Confirmed presence of amyloid pathology _____
 CMS Registry confirmation ALZH _____ (medicare and medicare advantage only)
 ApoE ε4 Testing (if available)
 Patient has been provided ARIA Risk Counseling
 Other: _____

Kisunla (donanemab-azbt) (Select one):**□ Standard dosing****Infusion 1:** Infuse 350 mg IV x1**Infusion 2:** Infuse 700 mg IV x 1, 4 weeks after Infusion 1**Infusion 3:** Infuse 1050 mg IV x1, 4 weeks after Infusion 2**Infusion 4 and beyond:** Infuse 1400 mg IV every 4 weeks, beginning 4 weeks after Infusion 3 Other: _____

**Medication will be infused over approximately 30 minutes.

**Using a 50ml 0.9% Sodium Chloride IV bag, flush IV tubing with NS 10 to 20 mL after each infusion.

 Refills: zero 6 months 12 months _____ (Prescription valid for one year, unless otherwise indicated)**Post Treatment Observations:** The patient is required to stay for 30 minutes following the first administration.**Special Instructions:** _____**PROVIDER INFORMATION**

Provider Full Name: _____ Provider NPI #: _____ Specialty: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

Contact Name: _____ Phone: _____ Fax: _____ Email: _____

Provider Name (Print)

Provider Signature

Date